Quantcast
Last updated on April 19, 2014 at 7:46 EDT

Latest Bevacizumab Stories

2013-12-10 16:24:54

INCLINE VILLAGE, Nev., Dec. 10, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2013, of approximately $109 million, as compared with actual revenue of $86 million for the fourth quarter of 2012, an approximate 27 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in revenues is driven by increased third quarter 2013 sales for Avastin(®),...

2013-12-09 08:28:49

Company invites individual and institutional investors to log-on to view presentation NEW YORK, Dec. 9, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their December 5th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat glioblastoma...

2013-12-02 16:23:39

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, Dec. 2, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat...

2013-11-22 08:23:18

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 22, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18(th) Annual Society for Neuro-Oncology (SNO) meeting in San Francisco. Enrollment in the...

2013-11-18 08:30:09

Neuro-Oncology experts from around the world will gather in San Francisco where data supporting the role of Tumor Treating Fields (TTFields) in treating recurrent glioblastoma brain tumors will be presented ST. HELIER, Jersey, Nov. 18, 2013 /PRNewswire/ -- Novocure announced today that 15 preclinical and clinical abstracts describing the latest aspects of NovoTTF(TM) Therapy will be presented at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO), which is...

2013-11-05 10:55:56

Study confirms that vascular normalization is the way these drugs improve patient survival Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, Massachusetts General Hospital (MGH) researchers report, those for whom treatment with the anti-angiogenic drug cediranib rapidly 'normalized' abnormal blood vessels around their...

2013-10-31 23:29:18

ResearchMoz include new market research report "Asia-Pacific Macular Degeneration Therapeutics Market to 2019: Industry Analysis, Size, Share, Growth, Trends And Forecast" to its huge collection of research reports. Click Here For Download Detail Report - http://www.researchmoz.us/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains-report.html Albany, NY (PRWEB) October 31, 2013 Macular...

2013-10-31 08:33:35

However, Changes in Treatment Practices Via Improved Originator Biologics Threaten Biosimilar Uptake, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar monoclonal antibodies initially; only a minority of oncologists say they will...

2013-10-30 23:27:54

RnRMarketResearch.com adds Latest Report on “Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 – Existing Angiogenics Retain Dominance Though High Unmet Need Remains” to its store. Dallas, TX (PRWEB) October 30, 2013 This report provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms;...

2013-10-17 12:30:28

Clinical data demonstrate CRLX101 is well suited for combination therapy CAMBRIDGE, Mass., Oct. 17, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that a poster on the combinability and efficacy data of Cerulean's Phase 2 candidate, CRLX101, has been selected as one of the top posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and will be one of four posters...